132 related articles for article (PubMed ID: 6930006)
1. Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment.
Munn S; Bailey RR; Begg E; Ebert R; Ferry DG
N Z Med J; 1980 Apr; 91(658):289-91. PubMed ID: 6930006
[TBL] [Abstract][Full Text] [Related]
2. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
Kirch W; Köhler H; Berggren G; Braun W
Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
[TBL] [Abstract][Full Text] [Related]
3. Quantitation in plasma and urine of acebutolol and a major metabolite with preliminary observations on their disposition kinetics in man.
Meffin PF; Harapat SR; Harrison DC
Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):31-51. PubMed ID: 968178
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics of acebutolol].
Collins RF
Nouv Presse Med; 1975 Dec; 4(46 Suppl):3223-8. PubMed ID: 768905
[TBL] [Abstract][Full Text] [Related]
5. Acebutolol in the treatment of patients with hypertension and renal functional impairment.
Begg E; Munn S; Bailey RR
N Z Med J; 1979 Apr; 89(634):293-5. PubMed ID: 286923
[TBL] [Abstract][Full Text] [Related]
6. Acebutolol pharmacokinetics in renal failure.
Smith RS; Warren DJ; Renwick AG; George CF
Br J Clin Pharmacol; 1983 Sep; 16(3):253-8. PubMed ID: 6626416
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of acebutolol-d6 in the rat correlates with the identification of a new metabolite in human urine.
Andresen BD; Davis FT
Drug Metab Dispos; 1979; 7(6):360-5. PubMed ID: 43220
[TBL] [Abstract][Full Text] [Related]
8. Observations on the pharmacokinetics of acebutolol.
Kaye CM; Kumana CR; Leighton M; Hamer J; Turner P
Clin Pharmacol Ther; 1976 Apr; 19(4):416-20. PubMed ID: 1269192
[TBL] [Abstract][Full Text] [Related]
9. [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].
Haufe CC; Sierakowski B; Jansa U; Stein G
Med Klin (Munich); 1994 Aug; 89(8):416-20. PubMed ID: 7968874
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of fleroxacin in renal impairment.
Weidekamm E
Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study of the disposition in man of acebutolol and its metabolite, diacetolol, using a new stereoselective hplc method.
Sankey MG; Gulaid A; Kaye CM
J Pharm Pharmacol; 1984 Apr; 36(4):276-7. PubMed ID: 6144783
[TBL] [Abstract][Full Text] [Related]
12. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
[TBL] [Abstract][Full Text] [Related]
13. Acebutolol and oral surgery: plasma levels following a single oral dose.
Fergusson NV; Dalgleish JG; Saunders DA
Ann R Coll Surg Engl; 1985 Mar; 67(2):124-6. PubMed ID: 3883878
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.
Flouvat B; Roux A; Chau NP; Viallet M; Andre-Fouet X; Woehrle R; Gregoire J
Eur J Clin Pharmacol; 1981 Mar; 19(4):287-92. PubMed ID: 7286031
[TBL] [Abstract][Full Text] [Related]
15. Using supported liquid extraction together with cellobiohydrolase chiral stationary phases-based liquid chromatography with tandem mass spectrometry for enantioselective determination of acebutolol and its active metabolite diacetolol in spiked human plasma.
Jiang H; Randlett C; Junga H; Jiang X; Ji QC
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jan; 877(3):173-80. PubMed ID: 19109073
[TBL] [Abstract][Full Text] [Related]
16. Enantioselective high performance liquid chromatographic assay of acebutolol and its active metabolite diacetolol in human serum.
Szymura-Oleksiak J; Walczak M; Bojarski J; Aboul-Enein HY
Chirality; 1999; 11(4):267-71. PubMed ID: 10224653
[TBL] [Abstract][Full Text] [Related]
17. A study of repeated administration of fenbufen in patients with chronic rheumatic disorders and renal impairment.
Armstrong R; Bradbrook I; Gibson TJ; Morrison P; Rogers HJ; Spector RG
Eur J Rheumatol Inflamm; 1982; 5(3):294-300. PubMed ID: 7084290
[TBL] [Abstract][Full Text] [Related]
18. Acebutolol metabolite plasma concentration during chronic oral therapy.
Winkle RA; Meffin PJ; Ricks WB; Harrison DC
Br J Clin Pharmacol; 1977 Oct; 4(5):519-22. PubMed ID: 911602
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study.
Zaman R; Jack DB; Wilkins MR; Kendall MJ
Biopharm Drug Dispos; 1985; 6(2):131-7. PubMed ID: 4005393
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.).
Gulaid AA; James IM; Kaye CM; Lewellen OR; Roberts E; Sankey M; Smith J; Templeton R; Thomas RJ
Biopharm Drug Dispos; 1981; 2(2):103-14. PubMed ID: 7248475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
